Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics

Aurinia Pharmaceuticals Inc (AUPH): $8.60

0.09 (-1.04%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add AUPH to Watchlist
Sign Up

AUPH Price/Volume Stats

Current price $8.60 52-week high $12.43
Prev. close $8.69 52-week low $4.07
Day low $8.54 Volume 1,849,700
Day high $8.99 Avg. volume 2,597,563
50-day MA $7.89 Dividend yield N/A
200-day MA $9.46 Market Cap 1.24B

AUPH Stock Price Chart Interactive Chart >

AUPH POWR Grades

  • AUPH scores best on the Value dimension, with a Value rank ahead of 75.88% of US stocks.
  • AUPH's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • AUPH's current lowest rank is in the Stability metric (where it is better than 3.89% of US stocks).

AUPH Stock Summary

  • AUPH's price/sales ratio is 7; that's higher than the P/S ratio of 86.88% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.28 for AURINIA PHARMACEUTICALS INC; that's greater than it is for just 16.61% of US stocks.
  • With a year-over-year growth in debt of 1,038.42%, AURINIA PHARMACEUTICALS INC's debt growth rate surpasses 98.91% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AURINIA PHARMACEUTICALS INC are NTRB, LUCD, POLA, TMDX, and SWAV.
  • AUPH's SEC filings can be seen here. And to visit AURINIA PHARMACEUTICALS INC's official web site, go to www.auriniapharma.com.

AUPH Valuation Summary

  • In comparison to the median Healthcare stock, AUPH's EV/EBIT ratio is 266.5% lower, now standing at -16.4.
  • AUPH's price/sales ratio has moved down 116.9 over the prior 112 months.

Below are key valuation metrics over time for AUPH.

Stock Date P/S P/B P/E EV/EBIT
AUPH 2023-11-03 7.4 3.0 -15.3 -16.4
AUPH 2023-11-02 7.1 2.9 -14.7 -15.8
AUPH 2023-11-01 6.4 2.6 -14.1 -14.7
AUPH 2023-10-31 6.6 2.7 -14.5 -15.1
AUPH 2023-10-30 6.6 2.7 -14.5 -15.1
AUPH 2023-10-27 6.4 2.6 -14.2 -14.8

AUPH Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at -175.45%.
  • Its 4 year price growth rate is now at 140.33%.
  • Its year over year price growth rate is now at -8.67%.
AUPH's revenue has moved up $128,681,000 over the prior 33 months.

The table below shows AUPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 128.999 -115.901 -115.456
2022-06-30 87.887 -140.789 -156.722
2022-03-31 66.316 -150.897 -168.217
2021-12-31 45.605 -157.692 -180.966
2021-09-30 72.231 -126.313 -170.2
2021-06-30 57.593 -116.343 -154.009

AUPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AUPH has a Quality Grade of D, ranking ahead of 9.07% of graded US stocks.
  • AUPH's asset turnover comes in at 0.178 -- ranking 206th of 682 Pharmaceutical Products stocks.
  • SVRA, SESN, and VSTM are the stocks whose asset turnover ratios are most correlated with AUPH.

The table below shows AUPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.178 0.992 -0.759
2021-06-30 0.133 0.994 -0.753
2021-03-31 0.125 0.999 -0.874
2020-12-31 0.131 1.000 -1.010
2020-09-30 0.000 1.000 -2.541
2020-06-30 0.001 1.000 -10.800

AUPH Price Target

For more insight on analysts targets of AUPH, see our AUPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.03 Average Broker Recommendation 1.31 (Strong Buy)

Aurinia Pharmaceuticals Inc (AUPH) Company Bio


Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.


AUPH Latest News Stream


Event/Time News Detail
Loading, please wait...

AUPH Latest Social Stream


Loading social stream, please wait...

View Full AUPH Social Stream

Latest AUPH News From Around the Web

Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 23, 2023

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Yahoo | November 20, 2023

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

ROCKVILLE, Md. & EDMONTON, Alberta, November 13, 2023--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

Yahoo | November 13, 2023

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

ROCKVILLE, Md. & EDMONTON, Alberta, November 07, 2023--Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with LN at ACR 2023

Yahoo | November 7, 2023

Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?

The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 7, 2023

Read More 'AUPH' Stories Here

AUPH Price Returns

1-mo 17.17%
3-mo -9.09%
6-mo -9.85%
1-year 67.64%
3-year -43.42%
5-year 41.91%
YTD 99.07%
2022 -81.11%
2021 65.37%
2020 -31.74%
2019 197.07%
2018 50.55%

Continue Researching AUPH

Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:

Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!